Then, in a mouse model, authors proved the effect of the tumor immune environment after ablation on distant tumors by demonstrating that the tumor-specific immune response induced by the combination of ablation and immunotherapy [anti-Programmed Cell Death Protein 1 (PD-1)] was stronger than anti-immune (anti-PD-1) or ablation alone (97). This evidence concerns the gene PDCD1 and neoplasm.